What is Altimmune's operating cash flow?

Altimmune (ALT) reported operating cash flow of -$20.94M in Q1 2026.

How has Altimmune's operating cash flow changed year-over-year?

Altimmune's operating cash flow decreased by 24.4% year-over-year, from -$16.84M to -$20.94M.

What is the long-term trend for Altimmune's operating cash flow?

Over 4 years (2021 to 2025), Altimmune's operating cash flow has grown at a -3.6% compound annual growth rate (CAGR), from -$78.24M to -$67.54M.

What does operating cash flow mean?

Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.

Altimmune ALT Operating Cash Flow

Operating Cash Flow at other companies

Eli LillyLLY

$5.33B+220%

Merck & Co.MRK

$3.92B+56.7%

Madrigal Pharmaceuticals, Inc.MDGL

-$167.44M-88.4%

Viking TherapeuticsVKTX

-$113.98M-118%

Wave Life SciencesWVE

-$59.55M+5.5%

MeiraGTx Holdings plcMGTX

$17.81M+148%

Other financials

Income statement

See full

Revenue$26.0K+420%

Operating income-$24.2M-11.1%

Net income-$22.6M-15.3%

EPS (diluted)-$0.18+30.8%

Balance sheet

See full

Cash & equivalents$97.6M+98.7%

Total debt$34.8M+14,092%

Total equity$284.0M+99.8%

Total assets$335.6M+113%

Cash flow

See full

CapEx$21.0K—

Free cash flow-$21.0M—

Valuation

See full

Market cap$558.14M-2.1%

Enterprise value$495.27M-5.0%

P/S13,613.2×-24,380×

Profitability

See full

Operating margin-230,461%-82,087pp

Net margin-214,861%-76,057pp

FCF margin-17,806.8%-110,030pp

Returns & leverage

See full

Return on equity-42.7%-8.7pp

Debt / equity0.1×+0.1×

Current ratio29.6×+13.7×

Where this comes from

Reported directly by Altimmune in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.

The official record: Altimmune’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Altimmune's operating cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Altimmune's operating cash flow?: Altimmune (ALT) reported operating cash flow of -$20.94M in Q1 2026.
How has Altimmune's operating cash flow changed year-over-year?: Altimmune's operating cash flow decreased by 24.4% year-over-year, from -$16.84M to -$20.94M.
What is the long-term trend for Altimmune's operating cash flow?: Over 4 years (2021 to 2025), Altimmune's operating cash flow has grown at a -3.6% compound annual growth rate (CAGR), from -$78.24M to -$67.54M.
What does operating cash flow mean?: Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.